首页/数据集/Depletion of Jak2V617F MPN-propagating stem cells by interferon-alpha in a murine model of polycythemia vera

Depletion of Jak2V617F MPN-propagating stem cells by interferon-alpha in a murine model of polycythemia vera

ChEBI2013-03-09 更新2026-07-21 收录

肿瘤靶向治疗

骨髓增殖性肿瘤

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-44961 数据链接链接失效反馈

官方服务：

资源简介：

Depletion of Jak2V617F MPN-propagating stem cells by interferon-alpha in a murine model of polycythemia vera

应用场景：

创建时间：

2013-03-09

肿瘤靶向治疗

药物耐药机制

Protein arginine methyltransferase 5 (PRMT5) over-expression in hematological and solid tumors methylates arginine residues on cellular proteins involved in important cancer functions including cell c

NIAID Data Ecosystem90

Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13)(p12;q12)

骨髓增殖性肿瘤

FGFR1-FIM融合基因

Chromosome 8p11–12 is the site of a recurrent breakpoint in a myeloproliferative disorder that involves lymphoid (T- or B-cell), myeloid hyperplasia and eosinophilia, and evolves toward acute leukemia

PubMed Central1998-05-12 更新40

Preclinical and first-in-human of Purinostat Mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed or refractory multiple myeloma and lymphoma

肿瘤靶向治疗

肿瘤免疫调节

Purinostat Mesylate (PM), a highly selective HDAC I/IIb inhibitor, exhibits excellent antitumor activity in multiple MM and lymphoma cell lines and multiple mouse models, outperforming the pan-HDAC in

NIAID Data Ecosystem20

肿瘤靶分子临床研究信息数据集

肿瘤靶向治疗

临床研究

聚焦肿瘤靶分子临床研究全流程，整合靶点发现、临床试验设计、疗效数据、安全性评估等核心信息。数据经标准化清洗与专业校验，关联靶点分子结构、作用机制及临床结果，支持科研机构靶点验证、药企药物研发、临床机构方案优化，为靶分子临床转化提供高质量、可溯源的数据支撑。

江苏数据交易所80

MYC-targeting by OMO-103 in solid tumours: a phase 1 trial

肿瘤靶向治疗

一期临床试验

A Phase I Dose-Escalation Study of a first-in-modality MYC inhibitor, OMO-103, in All-Comers Solid Tumors and identification of potential biomarkers

NIAID Data Ecosystem30